Divestment and equity financing of Biovitrum AB (SE) — SEK 1.6 billion

Carnegie acted as adviser to Pharmacia and Biovitrum AB in the spin-off and equity financing of the biotechnology company Biovitrum AB from a division within Pharmacia to a consortium led by MPM Capital and Nordic Capital. Biovitrum AB is active in research into metabolic diseases and recombinant proteins. July, 2001.